Choose your category
- All
- CONTENT
- CORPORATE
- CSR
- EVENT
- PRODUCT
- SCIENCE
- TRENDS
This year again, Lactalis Ingredients Pharma will be present at CPHI Milan from October 6–8, 2026, at Fiera Milano. Our team will be pleased to welcome you at Booth 1F65.
Artificial intelligence is progressively entering pharmaceutical formulation workflows, particularly in areas such as compatibility screening, dissolution profile prediction, formulation optimization and process modelling. These applications are promising, but their value depends strongly on the quality, consistency and traceability of the data used to train and validate the models.
On the occasion of the publication of the Lactalis Group’s 2025 CSR Report, Lactalis Ingredients Pharma reaffirms its commitment to a sustainable future. Driven by the Group’s new CSR programme, “Our Sustainable Way to Go”, Lactalis is accelerating its local initiatives to combine expertise, quality, and resource preservation.
Maeva Croué was invited to appear on the set of Talk de la Rédaction by L’Usine Nouvelle for an interview focusing on the pharmaceutical industry. The discussion explored a key question shaping the sector today: “From sovereignty to performance: what strategic transformations are needed for the pharmaceutical industry?”
A significant proportion of new drug candidates present limited aqueous solubility. This is a well-documented formulation challenge, particularly for oral solid dosage forms, where the performance of the final product depends not only on the API itself, but also on the way the formulation supports dissolution under physiological conditions.
In oral solid dosage forms, lactose is often described as a filler. This description is accurate, but it can be incomplete. Depending on its grade, particle size distribution and physicochemical characteristics, pharmaceutical lactose can contribute to several formulation parameters, including blend behaviour, tablet structure, disintegration and the conditions in which an API becomes available for dissolution.
Since the Valsartan crisis in 2018, attention has shifted to an impurity that had long remained under the radar: nitrosamines. These potent genotoxic impurities, classified as probable human carcinogens, are not the result of isolated external contamination but a byproduct of specific chemical conditions during the manufacturing process. [1] Following global recall and media coverage, new quality control mandates were implemented, and Nitrosamines risk management is now a core component of drug development and quality control. What was once perceived as an API-related issue is now understood as a broader challenge, involving the entire value chain.
